Greenwich LifeSciences rises after EMA update for breast cancer drug

Greenwich Lifesciences

09/07/2026 12:29

** Shares of biotech firm Greenwich LifeSciences GLSI.O rise 10.2% to $20.79 premarket 
** Co says European Medicines Agency will allow use of GP2, a commercially manufactured protein fragment, in a late-study study for its experimental breast cancer drug in Europe
** GP2 is a short fragment from HER2, a protein found in many breast cancers; it is part of GLSI's drug, GLSI-100, designed to help prevent recurrence of breast cancer after surgery
** Co says all 170-180 U.S. and European study sites are expected to use the same GP2 lot; shipments to European pharmacies have started
** GLSI is also seeking approval to use the same GP2 lot in the UK and Canada through separate regulatory processes
** More than 1,300 patients have been screened; preliminary data showed a 70%-80% reduction in recurrence rates, though results may differ by study end - GLSI 
** As of last close, GLSI down 10.2% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))